Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030

Prediction: 1 Biotech Stock That Could Surpass Pfizer by 2030

24/7 Wall St. Insights: Pfizer (PFE) has been a behemoth in pharmaceuticals and drug development for decades, but lately has run into headwinds from vaccine sales, patent expiry, and more. That opens the door for smaller rivals pursuing novel and innovative technologies and therapies to usurp Pfizer’s crown by 2030. Nvidia made early investors rich, but there is a new class of ‘Next Nvidia Stocks’ that could be even better. Click here to lear…